These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17027836)

  • 21. [Hyperuricemia in hypertension].
    Tatsuno I; Saito Y
    Nihon Rinsho; 2001 May; 59(5):967-72. PubMed ID: 11392000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Gottdiener JS
    Circulation; 1999 Aug; 100(6):685-6. PubMed ID: 10490345
    [No Abstract]   [Full Text] [Related]  

  • 23. The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid?
    Reyes AJ; Leary WP
    Cardiovasc Drugs Ther; 2002 Dec; 16(6):485-7. PubMed ID: 12797357
    [No Abstract]   [Full Text] [Related]  

  • 24. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients.
    Kostka-Jeziorny K; Uruski P; Tykarski A
    Blood Press; 2011 Apr; 20(2):104-10. PubMed ID: 21405957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension.
    Meredith PA; Murray LS; McInnes GT
    J Hum Hypertens; 2010 Aug; 24(8):525-31. PubMed ID: 20016523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.
    Ishimitsu T; Ohno E; Nakano N; Furukata S; Akashiba A; Minami J; Numabe A; Matsuoka H
    Clin Exp Hypertens; 2011; 33(6):366-72. PubMed ID: 21797795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diuretics and serum uric acid].
    Christensen P; Espersen O; Hvidt R; Jorgensen P; Lund-Sorensen J; Påby P; Hvidt S
    Ugeskr Laeger; 1974 Sep; 136(37):2075-80. PubMed ID: 4409261
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G; Fuchs W
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
    Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
    MMW Fortschr Med; 2008 Feb; 150(6):40. PubMed ID: 18323344
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AT1 blockers and uric acid metabolism: are there relevant differences?
    Puig JG; Torres R; Ruilope LM
    J Hypertens Suppl; 2002 Jun; 20(5):S29-31. PubMed ID: 12184060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study.
    Rachmani R; Levi Z; Zadok BS; Ravid M
    Clin Pharmacol Ther; 2002 Sep; 72(3):302-7. PubMed ID: 12235451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H; Ogihara T
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihypertensive effects of metolazone (zaroxolyn).
    Materson BJ; Oster JR; Perez-Stable EC
    Curr Ther Res Clin Exp; 1974 Sep; 16(9):890-6. PubMed ID: 4214663
    [No Abstract]   [Full Text] [Related]  

  • 36. Blockade of angiotensin II and aging: is the spontaneously hypertensive rat a suitable model?
    Tuttle JB
    J Hypertens; 2006 Jan; 24(1):27. PubMed ID: 16331094
    [No Abstract]   [Full Text] [Related]  

  • 37. [Comparison with other antihypertensive drugs, especially with ACEI].
    Hiwada K
    Nihon Rinsho; 1999 May; 57(5):1187-93. PubMed ID: 10361454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uric acid in hypertension and cardiovascular disease.
    Alderman M
    Can J Cardiol; 1999 Nov; 15 Suppl F():20F-2F. PubMed ID: 10579748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The increase in serum uric acid induced by diuretics could be beneficial to cardiovascular prognosis in hypertension: a hypothesis.
    Reyes AJ; Leary WP
    J Hypertens; 2003 Sep; 21(9):1775-7. PubMed ID: 12923414
    [No Abstract]   [Full Text] [Related]  

  • 40. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
    Milionis HJ; Elisaf MS
    Curr Med Res Opin; 2000; 16(3):164-70. PubMed ID: 11191005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.